Article
Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 1 Mar 2015
Zheng Chenghong, Li Xiaochao, Kong Caixia, Ke Shuhong, Peng Cong, Cui Tianpen, Gao Mingsong, Zhou Yang, Guo Wei, Huang Lianqi, Petersen Robert B, Huang Kun
Abstract excerpt
Hypofibrinolysis is commonly found in patients with diabetes mellitus and is associated with the increased risk for many diabetic complications. An important inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), participates in hypofibrinolysis in diabetes mellitus and may be involved in diabetic macrovascular disease. The present study was designed to determine whether TAFI polymorphisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
